The problem with the CV area IMO is that the blood pressure market is pretty well served.
There is a dramatic need for new and efficacious heart failure drugs, though the clinical trials are long, need many patients, and the cardiorenal division requires an outcomes study, and the drug candidate needs to be additive to the current standard of care. The current SOC includes a diuretic, a blood pressure lowering drug, a beta blocker, potentially an aldosterone antagonist, and potentially a rate control drug in the near future. The new drug candidate needs to be essentially "as safe as mother's milk". Nevertheless this is a good area for PFE to stay or get back in if they have good mechanisms to go after. PFE needs blockbusters. Not a good area for small, cash strapped biotechs, unless they have a committed partner.
Market Data 
Markets 
AI
